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Abstract
Background: Worldwide, the emergence of multidrug-resistant gram-negative bacteria is a clinical problem. Surface
disinfectant cleaners (SDCs) that are effective against these bacteria are needed for use in high risk areas around
patients and on multi-touch surfaces. We determined the efficacy of several SDCs against clinically relevant bacterial
species with and without common types of multidrug resistance.
Methods: Bacteria species used were ATCC strains; clinical isolates classified as antibiotic-susceptible; and multi-resistant
clinical isolates from Klebsiella oxytoca, Klebsiella pneumoniae, and Serratia marcescens (all OXA-48 and KPC-2); Acinetobacter
baumannii (OXA-23); Pseudomonas aeruginosa (VIM-1); and Achromobacter xylosoxidans (ATCC strain). Experiments were
carried out according to EN 13727:2012 in quadruplicate under dirty conditions. The five evaluated SDCs were based on
alcohol and an amphoteric substance (AAS), an oxygen-releaser (OR), surface-active substances (SAS), or surface-active-
substances plus aldehydes (SASA; two formulations). Bactericidal concentrations of SDCs were determined at two
different contact times. Efficacy was defined as a log10≥ 5 reduction in bacterial cell count.
Results: SDCs based on AAS, OR, and SAS were effective against all six species irrespective of the degree of
multi-resistance. The SASA formulations were effective against the bacteria irrespective of degree of multi-resistance
except for one of the four P. aeruginosa isolates (VIM-1). We found no general correlation between SDC efficacy and
degree of antibiotic resistance.
Conclusions: SDCs were generally effective against gram-negative bacteria with and without multidrug resistance. SDCs
are therefore suitable for surface disinfection in the immediate proximity of patients. Single bacterial isolates, however,
might have reduced susceptibility to selected biocidal agents.
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Background
Healthcare-associated infections, especially with multidrug-
resistant gram-negative bacteria (MRGN) are an emerging
problem in infection control [1]. MRGN are responsible for
serious infections and have a significant impact on morbid-
ity and mortality [2]. The spread of these organisms as well
as the spread of resistance genes is an emerging public
health issue [3,4]. Only limited therapeutic options are
available and finding effective and suitable antibiotic drugs
to treat infections can be difficult.
The main influence on the development of antibiotic
drug resistance is antibiotic use, both the total amount of
antibiotics used and the distribution of antimicrobial clas-
ses. For example, data from Germany show that despite a
stable total amount of antibiotics used between 2001 and
2008, carbapenem use doubled. This was associated with
an increase in carbapenem-resistant Klebsiella pneumonia,
carbapenemase-producing bacteria and imipenem-resistant
Acinetobacter baumannii [5].
Once resistance is established, MRGN spread, especially
with global travel [6]. Reports of MRGN outbreaks are
abundant in the literature [7,8]. Recent data from Russia
show that extensively drug-resistant Pseudomonas aerugi-
nosa spread rapidly throughout Russia and into Belarus
and Kazakhstan [9]. The damage of MRGN must be lim-
ited by preventing transmission.
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This strategy is reflected in a 2012 recommendation from
the Commission for Hospital Hygiene and Infectious Dis-
ease Prevention (KRINKO) at the Robert Koch-Institute in
Germany for handling patients infected or colonized with
MRGN. In 2014, the ESCMID also published a guideline
on infection control measures MRGN in hospitalized pa-
tients [10]. In contrast to the more epidemiologically based
approach of Magiorakos et al. [11], the German recommen-
dation focused on the clinical relevance of the resistance
pattern. For individual pathogens, the most important anti-
biotics for treating severe infections were determined by
resistance pattern (acylureidopenicillins, third-generation
and fourth-generation cephalosporins, carbapenems, and
fluoroquinolones). According to the KRINKO definition,
3MRGN are resistant to three of these four classes;
4MRGN are gram-negative microorganisms resistant to all
four classes and include pan-resistant microorganisms. The
recent ESCMID guideline does not distinguish different
resistance patterns within MRGN [10].
A key factor in prevention of MRGN infections is the
consequent implementation and compliance with effective
hygiene measures [12,13] which is also described in the
ESCMID guideline [10]. Targeted surface disinfection is a
major measure of standard infection control. The surface
disinfectants must be effective against the targeted patho-
gens. Surfaces near patients and high-touch surfaces must
be effectively disinfected.
Surface disinfectant cleaners (SDCs) that are often used
for this purpose and can be used in the immediate proxim-
ity of patients are usually based on surface-active ingredi-
ents such as quaternary ammonium compounds (QACs).
Some data indicate that adaptation or resistance to QACs
can develop and QACs have greater activity against gram-
positive bacteria compared to gram-negative bacteria
[14,15]. Therefore, we determined the efficacy of several
common SDCs against clinically relevant bacterial species
with and without common types of multidrug resistance.
Methods
Test products
Five SDCs were tested at the concentration which is listed
to be bactericidal using standard test bacteria (Table 1).
Bacillol 30 foam, based on alcohols and an amphoteric
substance (AAS) was tested undiluted for 30 and 60 s;
Mikrobac forte, based on surface-active substances (SAS)
was tested at 0.5% for 30 and 60 min; Dismozon plus,
based on an oxygen-releaser (OR), was tested at 0.4% for
30 and 60 min; Kohrsolin extra, based on surface-active
substances and an aldehyde (SASA1), was tested at 0.25%
for 30 and 60 min; and Kohrsolin FF, based on surface-
active substances and an aldehyde (SASA2), was tested at
0.5% for 30 and 60 min. All SDCs were manufactured by
Bode Chemie GmbH, Hamburg, Germany. Products were
blinded for the investigation.
Tested bacterial species
Bacterial species were selected because they are specifically
mentioned in the German and the European recommenda-
tion (K. pneumoniae, P. aeruginosa, A. baumannii) [10,13],
or because they have been described before to be potentially
less susceptible to selected biocidal agents of SDCs (Serra-
tia marcescens, Klebsiella oxytoca, Achromobacter xylo-
soxidans) [16-18]. They were used as: S. marcescens
(ATCC 14756 and four clinical isolates: antibiotic-
susceptible (“0MRGN”), 3MRGN, 4MRGN OXA-48
and 4MRGN KPC-2); K. pneumoniae (ATCC 10031 and
four clinical isolates: antibiotic-susceptible, 3MRGN,
4MRGN OXA-48 and 4MRGN KPC-2); K. oxytoca
(ATCC 700324 and four clinical isolates: antibiotic-
susceptible, 3MRGN, 4MRGN OXA-48 and 4MRGN
KPC-2); P. aeruginosa (ATCC 15442 and three clinical iso-
lates: antibiotic-susceptible, 3MRGN and 4MRGN VIM-1);
A. baumannii (ATCC 19606 and two clinical isolates:
antibiotic-susceptible and 4MRGN OXA-23); and A. xylo-
soxidans (ATCC 27061). The eight 4MRGN isolates were
from the National Reference Laboratory for multidrug-
resistant gram-negative bacteria, Ruhr University Bochum,
Germany. The five antibiotic-susceptible isolates and four
3MRGN isolates were kindly provided by the Laboratory
Fenner, Hamburg, Germany.
Determination of bactericidal activity
All experiments were carried out at Labor L + S AG, Bad
Bocklet, Germany, according to EN13727:2012 which is
Table 1 Surface disinfectant cleaners, their active ingredients and bactericidal concentration as listed by the
Commission for disinfectants [53]
Product Abbreviation Active ingredients Bactericidal concentration
(exposure time)
Bacillol® 30 foam AAS Ethanol; propan-2-ol; propan-1-ol; N-alkyl-aminopropylglycine Undiluted (30 s)
Mikrobac® forte SAS Benzyl-C12-18-alkyldimethylammonium chlorides; N-(3-aminopropyl)-N
dodecylpropane-1,3-diamine
0.5% (1 h)
Dismozon® plus OR Magnesium monoperoxyphthalatehexahydrate 0.4% (1 h)
Kohrsolin® extra SASA1 (Ethylenedioxy) dimethanol; Glutaral; Didecyldimethylammonium chloride 0.25% (1 h)
Kohrsolin® FF SASA2 Glutaral; Benzyl-C12-18-alkyldimethylammonium chlorides;
Didecyldimethylammonium chloride
0.5% (1 h)
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the suspension test to determine the spectrum of bacteri-
cidal activity of disinfectants used in human medicine
[19]. All tested products are used as disinfectant cleaners
so dirty conditions with an interfering substance of 0.3%
bovine albumin and 0.3% sheep erythrocytes were used.
Each experiment was carried out in quadruplicate on
different test days and by different investigators.
From a second subculture on agar plates, a test suspen-
sion was adjusted to 1.5–5.0 × 108 colony forming units
(cfu) per ml. To 1 ml test suspension, 1 ml interfering sub-
stance with 3% bovine albumin and 3% sheep erythrocytes
was added and mixed. The mixture was placed in a water
bath (20 ± 1°C) for 2 min and 8 ml of tested product was
added. After mixing, the tube was placed in the water bath
for the indicated time, mixed again before the end of incu-
bation, and 1 ml added to a tube with 8 ml neutralizing
broth (3.0% Tween 80, 3.0% saponin, 0.1% histidine, 0.1%
cysteine in tryptic soy broth) and 1 ml water. After mix-
ing, the tube was placed in the water bath for 5 min (for
30 or 60 min contact times) or 10 s (for 30 or 60 s contact
times). Neutralizing agents were validated for all SDCs
using all species as ATCC strains. At the end of
neutralization, the sample was mixed, and diluted 1:10
with neutralizing broth. 0.5 ml of sample without dilution
was plated in quadruplicate and 0.5 ml of each dilution
step in duplicate on TSA containing neutralizers (Biomér-
ieux, Nürtingen, Germany and heipha Dr. Müller GmbH,
Eppelheim, Germany). Plates were incubated at 37 ± 1°C
for 48 h and colonies per plate counted. All plates from a
dilution step with <330 cfu were used to calculate the
number of cfu/mL in a sample of disinfectant, test organ-
ism, and interfering substance. Data were converted to
log10 scale. Bacterial reduction was calculated as viable
colonies before exposure to a disinfectant minus viable
colonies after exposure. The EN13727 requirement for
bactericidal activity is a log10 reduction ≥5 within the
chosen contact time. Controls for experimental conditions
and neutralizer, and dilution neutralization validation were
carried out according to EN 13727.
Data presentation
When all four experiments per product, test organism and
time indicated a log10 reduction ≥5, the lowest log10 re-
duction of the four results is presented. If the four experi-
ments indicated a log10 reduction <5, mean and standard
deviation were calculated. A general correlation between
efficacy of a SDC and bacterial antibiotic-resistance status
was assumed if a SDC was less effective against a 4MRGN
compared to a 3MRGN and if it was at the same time less
effective against a 3MRGN compared to a 0MRGN.
Results
All AAS, SAS, and OR products were effective (≥5 log10-
reduction) against all tested species, the ATCC strains and
the clinical isolates with and without multidrug-resistance
(Tables 2 and 3). No efficacy gap was observed among the
products against the tested gram-negative strains. SASA
products were also comprehensively effective against S.
marcescens, K. pneumonia, K. oxytoca, A. baumannii and
A. xylosoxidans, both ATCC strains and clinical isolates
with and without multidrug-resistance. They were also
effective against P. aeruginosa ATCC 15442, 0MRGN and
3MRGN but were not sufficiently effective against
4MRGN VIM-1 with a mean log10-reduction of 1.54–3.45
(Table 3). No general correlation was seen between
efficacy of all five SDC and bacterial antibiotic-resistance
status with five of six bacterial species (25 possible correla-
tions). It was also not seen for three SDCs with P. aerugi-
nosa (3 possible correlations). It was partly seen for 2 SASA
products with P. aeruginosa but only for the comparison of
4MRGN versus 3MRGN and not for the comparison
3MRGN versus 0MRGN.
Discussion
All SDCs containing SAS were generally effective against
MRGN. Literature reports on SAS efficacy are conflicting.
Some studies found that SAS are not sufficiently effective
against gram-negative bacteria or that efficacy is lower
against gram-negative than against gram-positive bacteria
[14,20-23]. Other studies found that SAS are effective
[24,25]. Outbreaks of contaminated SAS disinfectant solu-
tions have been reported [26-28]. Some strains, particu-
larly biofilm-forming species, survive or even multiply in
SAS disinfectants at concentrations at which they are
normally used and this can result in infections such as
septicemia [29,30]. Our results did not support the
hypothesis that SAS-containing products are insufficiently
effective against gram-negative bacteria. We found that
SAS products were highly effective against multiple clinic-
ally relevant gram-negative microorganisms.
The link between lower susceptibility to SAS and anti-
biotic resistance is not conclusively established [31,32]. No
resistance breakpoints have been defined for biocides so
defining resistance to these compounds is difficult. In
addition, reversible adaptations to an active ingredient ver-
sus stable resistance must be distinguished [33,34]. SAS
are used for multiple applications, e.g., in the cosmetic,
pharmaceutical, and food industries. Adaptation and
resistance have been shown for different species. For
gram-negative bacteria, cross-resistance to different antibi-
otics and to different types of SAS, and selection for
antibiotic-resistant strains has been found [35,36]. Anti-
biotic resistance and resistance to biocides can have the
same molecular mechanisms, although biocides generally
show a broader activity because their mode of action is
nonspecific [37-39]. The association between antibiotic-
resistance and biocide-resistance seen in gram-negative
bacteria can be explained by a link between the genes for
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Table 2 Log10-reduction of cell counts by five surface disinfectant cleaners against emerging multidrug-resistant
enterobacteriaceae and corresponding ATCC strains
Species Isolate/strain Product (concentration) Contact time Log10-reduction
Serratia marcescens ATCC 14756 AAS (undiluted) 30 and 60 s > 5.47




0MRGN AAS (undiluted) 30 and 60 s > 5.37




3MRGN AAS (undiluted) 30 and 60 s > 5.17




4MRGN OXA-48 AAS (undiluted) 30 and 60 s > 5.14




4MRGN KPC-2 AAS (undiluted) 30 and 60 s > 5.09




Klebsiella pneumoniae ATCC 10031 AAS (undiluted) 30 and 60 s >5.34




0MRGN AAS (undiluted) 30 and 60 s >5.08




3MRGN AAS (undiluted) 30 and 60 s > 5.09




4MRGN OXA-48 AAS (undiluted) 30 and 60 s >5.38
SAS (0.5%) 30 and 60 min
OR (0.4%)
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both resistance mechanisms [40]. Of note, studies on resist-
ance are often carried out with concentrations of surface
disinfectants lower than what is normally used. To avoid
concentrations of SDC that are sublethal to bacteria, rec-
ommended concentrations and contact times must be
known and used.
We did not find a general correlation between antibiotic-
resistance patterns and susceptibility to SAS-containing
products, consistent with earlier reports [41]. Only a single
4MRGN P. aeruginosa isolate had lower susceptibility to
the two aldehyde-containing SAS products. Nonetheless,
the products were highly effective against three other
P. aeruginosa isolates indicating that reduced susceptibil-
ity was strain-specific. Individual clinical strains can show
reduced susceptibility to aldehyde [42,43]; especially for
some P. aeruginosa strains, published data are available on
the lower efficacy of aldehyde-containing products [44-46].
We do not know the underlying mechanism of the reduced
susceptibility of the isolate in our study. However, deter-
mining the molecular mechanism of the lowered suscepti-
bility would be interesting and help to better understand
our findings.
We found that products based on an OR compound or
AAS were highly effective. A few studies with alcohol-
Table 2 Log10-reduction of cell counts by five surface disinfectant cleaners against emerging multidrug-resistant
enterobacteriaceae and corresponding ATCC strains (Continued)
SASA1 (0.25%)
SASA2 (0.5%)
4MRGN KPC-2 AAS (undiluted) 30 and 60 s >5.34




Klebsiella oxytoca ATCC 700324 AAS (undiluted) 30 and 60 s >5.14




0MRGN AAS (undiluted) 30 and 60 s >5.36




3MRGN AAS (undiluted) 30 and 60 s >5.31




4MRGN OXA-48 AAS (undiluted) 30 and 60 s >5.31




4MRGN KPC-2 AAS (undiluted) 30 and 60 s >5.11




Experiments were carried out in quadruplicate under dirty conditions; lowest log10-reduction values are shown.
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Table 3 Log10 reduction of cells counts by five surface disinfectant cleaners against emerging multidrug-resistant
non-fermenting bacteria and corresponding ATCC strains
Species Isolate/strain Product (concentration) Contact time Log10-reduction
Pseudomonas aeruginosa ATCC 15442 AAS (undiluted) 30 and 60 s >5.28




0MRGN AAS (undiluted) 30 and 60 s >5.14




3MRGN AAS (undiluted) 30 and 60 s >5.06




4MRGN VIM-1 AAS (undiluted) 30 s and 60 s >5.45
SAS (0.5%) 30 and 60 min
OR (0.4%)
SASA1 (0.25%) 30 min 1.54 ± 0.91
60 min 1.76 ± 0.94
SASA2 (0.5%) 30 min 3.04 ± 0.73
60 min 3.45 ± 0.55
Acinetobacter baumannii ATCC 19606 AAS (undiluted) 30 and 60 s >5.20




0MRGN AAS (undiluted) 30 and 60 s >5.09




4MRGN OXA-23 AAS (undiluted) 30 and 60 s >5.14




Achromobacter xylosoxidans ATCC 27061 AAS (undiluted) 30 and 60 s >5.13




Experiments were carried out in quadruplicate under dirty conditions; lowest log10 reduction values or mean and standard deviation are shown.
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based hand rubs revealed that they are effective against
multidrug-resistant bacterial isolates including multidrug-
resistant Mycobacterium tuberculosis [47,48]. No studies
have found that OR compounds used on surfaces are not
fully effective against bacteria. Both OR and AAS are con-
sidered to have a nonspecific mechanism of action [49]
and are volatile (alcohol) or degradable (OR compounds).
Therefore, acquired bacterial resistance to OR or AAS
products is very unlikely.
A limitation of this study for clinical practice is experi-
ments were carried out with bacteria in suspension and not
under practical conditions. Suspension tests are the first-
choice method for studying the spectrum of antimicrobial
activity of disinfectants [50]. Testing the effectiveness of the
formulations under practical conditions would also be
interesting. In Europe, a test method is currently being
developed to determine both the efficacy of surface disin-
fectants on a contaminated test field and the potential to
spread of bacteria by wiping to non-contaminated surfaces
[51]. Future research could determine the effectiveness of
SDCs tested under practical conditions.
Recent data from Germany show that the percentage of
MRGN in a hospital exceeded nosocomial infection rates
by MRSA and VRE (8% vs. 2% for MRSA and VRE) [52].
The main reason is that once multidrug-resistance is
established, the spread of resistant strains is inevitable.
Currently, no effective sanitation methods exist against
MRGN carriers. Even with contact precautions in patient
care, standard hygiene measures are still essential for
preventing of transmission of MRGN. Targeted surface
cleaning and disinfection is an element of standard hy-
giene in hospitals.
Conclusions
Our data showed that SDCs with different active ingredi-
ents were generally effective against a variety of emerging
multidrug-resistant bacterial species.
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